Nevertheless, the Impassion 130 study indicated clinically meaningful prolonged overall survival for PD-L1 positive patients with tumor-infiltrating immune cell (IC) score greater than 1% when atezolizumab combined with nab-paclitaxel were used as first-line treatment for unresectable local advanced or metastatic triple-negative breast cancer (TNBC)5. This evidence concerns the gene CD274 and neoplasm.